Literature DB >> 11585099

Treatment of viral hepatitis--2001.

S C Gordon1.   

Abstract

Chronic viral hepatitis may now be controlled and, in many cases, permanently eradicated. Rapid advances in the antiviral therapy of chronic hepatitis C infection have resulted in a greater than 50% sustained response rate, with genotypes 2 and 3 now considered 'curable diseases.' Current hepatitis B therapy leads to significant improvement in liver histology and overall survival. These advances, coupled with the fact that 8% of the world population is chronically infected with viral hepatitis, has sparked considerable interest in this condition on the part of the pharmaceutical industry. In 2001, the most effective therapy for chronic hepatitis C is the combination of pegylated interferon alpha and oral ribavirin. The treatment of hepatitis B consists of either interferon alpha or oral lamivudine, while newer nucleoside/nucleotide analogues, alone or in combination with existing therapy, are being explored.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585099     DOI: 10.3109/07853890108995951

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  2 in total

1.  Persistent BBB disruption may underlie alpha interferon-induced seizures.

Authors:  Lev Pavlovsky; Ernst Seiffert; Uwe Heinemann; Akiva Korn; Haim Golan; Alon Friedman
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

2.  Effect of Fuzheng Huayu capsule combined with Pegasys on genotype 1 hepatitis C fibrosis and cell apoptosis.

Authors:  Bo Zhang; Mintao Hu; Lihua Huang; Yunchuan Pu; Hao Pei; Zhong Hua; Shangzhi Yao
Journal:  Exp Ther Med       Date:  2014-08-08       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.